Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SCP.WA
Strong SellSinkerScope Fluidics S.A. · Healthcare · Poland · $116M · Avg Vol: $75K/d
COMPANY DESCRIPTION
Scope Fluidics S.A. is a biotechnology company that develops innovative microfluidic systems for point-of-care medical diagnostics, notably the PCR ONE and BacterIO systems. The company's competitive advantage lies in its proprietary IP portfolio and its proven track record of developing diagnostic platforms from concept to high-value divestment. It operates as a high-potential incubator in the global diagnostics market.
FINANCIAL SUMMARY (PLN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4M | 0.5M | 0.1M | 0.1M | -37.2% | 0.1M | 2.5M | — | 2400.0% |
| EPS (PLN) | 118.35 | -6.89 | 24.00 | -14.64 | -55.0% | -16.97 | -17.20 | 126.40 | 74.0% |
| Shares | 2.7M | 2.7M | 2.7M | 3.2M | +16.2% | 3.2M | — | — | — |
| Debt | 2.5M | 2.4M | 1.6M | 2.1M | -4.3% | 2.3M | — | — | — |
| Equity | 333.0M | 80.9M | 146.4M | 162.4M | -21.3% | — | — | — | — |
| Op CF | -28.2M | -19.1M | -25.1M | -46.1M | — | -51.4M | — | — | — |
| Inv CF | 371.1M | -12.0M | 88.9M | -50.6M | — | — | — | — | — |
| Fin CF | -30.3M | -234.2M | -1.1M | 60.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SCP.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SCP.WA | Scope Fluidics S.A.(you) | $116M | 11 | Strong Sell |
| SLV.WA | Selvita S.A. | $132M | 40 | Hold |
| VOX.WA | Voxel S.A. | $374M | 88 | Strong Buy |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $120M | 6 | Strong Sell |
| BCX.WA | Bioceltix S.A. | $118M | 18 | Strong Sell |
| RVU.WA | Ryvu Therapeutics S.A. | $113M | 4 | Strong Sell |
| S2B.WA | Syn2bio S.A. | $148M | 3 | Strong Sell |
| MDG.WA | Medicalgorithmics S.A. | $75M | 16 | Strong Sell |
| SVE.WA | Synthaverse S.A. | $46M | 11 | Strong Sell |
| DIA.WA | Diagnostyka S.A. | $1.5B | 81 | Strong Buy |
Peer medians: ROE -16.3% · P/E 17.0x · Gross margin 32.5%